Chronic Active Crohn's Disease Research Articles

Anti-sense ICAM-1 (ISIS-2302) for subcutaneous treatment of chronic active Crohn's disease (CACD): Lack of efficacy in a prospective, double-blind, multicenter randomized trial

Anti-sense ICAM-1 (ISIS-2302) for subcutaneous treatment of chronic active Crohn's disease (CACD): Lack of efficacy in a prospective, double-blind, multicenter randomized trial

Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease

Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease

Anti-TNF alpha: new therapy for Crohn's disease.

Immunological technology has paved the way for a promising new therapy for patients suffering from chronic active Crohn's disease. Neutralization of tumor necrosis factor-alpha (TNF alpha), a cytokine secreted by cells in the immune system, may prove useful in decreasing bowel inflammation and aid in the closure of fistulae. Two multicenter, randomized, double-blinded, placebo-controlled trials were conducted to evaluate the safety and efficacy of inflixmab (Remicade [Centocor]), a chimeric monoclonal antibody form of anti-TNF alpha, hypothesized to provide a prolonged therapeutic effect in chronic inflammation. The 5 mg/kg dose regimen of infliximab was the lowest effective dose and produced a high degree of benefit lasting 8 weeks to 3 months. Infusion preparation, cost, and patient indications bear special considerations. Further investigation is needed in long-term safety and efficacy for chronic administration of infliximab.

New insights into the pathogenesis of anemia of chronic diseases: Induction of ferritin synthesis and development of anemia during recombinant human interleukin-10 (rHuIL-10) treatment of chronic active Crohn's disease (CACD)

• G4499 NEW INSIGHTS INTO THE PATHOGENESIS OF ANEMIA OF CHRONIC DISEASES: INDUCTION OF FERRITIN SYNTHESIS AND DEVELOPMENT OF ANEMIA DURING RECOMBINANT HUMAN INTERLEUKIN-10 (rHuIL-10) TREATMENT OF CHRONIC ACTIVE CROHN'S DISEASE (CACD). H. Tilg, A. Kaser, Innsbruck, Austria; S. Schreiber, Berlin, Germany; M. Gregor, Ttibingen, Germany; P. Rutgeerts, Leuven, Belgium; S. van Deventer, Amsterdam, The Netherlands; C. Gasche, Vienna, Austria; J.C. Koningsberger, Utrecht, The Netherlands; L. Abreu, Madrid, Spain; B. Duclos, Strasbourg, France; R.A. van Hogezand, Leiden, The Netherlands; M. Cohard, P. Grint, Kenilworth, NJ, USA; G. Weiss, Innsbruck, Austria.

Recombinant human interleukin-10 (rHuIL-10) therapy in steroid-refractory chronic active Crohn's disease (CACD): Induction of neopterin, a degradation product of the pteridine pathway regulated by interferon-gamma

Recombinant human interleukin-10 (rHuIL-10) therapy in steroid-refractory chronic active Crohn's disease (CACD): Induction of neopterin, a degradation product of the pteridine pathway regulated by interferon-gamma

Randomised trial of mycophenolate mofetil versus azathioprine for treatment of chronic active Crohn's disease

Randomised trial of mycophenolate mofetil versus azathioprine for treatment of chronic active Crohn's disease

A safety and efficacy study of recombinant human interleukin-10 (rHuIL-10) treatment in 329 patients with chronic active Crohn's disease (CACD)

A safety and efficacy study of recombinant human interleukin-10 (rHuIL-10) treatment in 329 patients with chronic active Crohn's disease (CACD)

Immunomodulation of Crohn's disease by interleukin-10.

Interleukin-10 is an important cytokine that is involved in regulation of pro-inflammatory cytokines and T-cell responses. Interleukin-10 has been studied extensively in various preclinical and clinical models of inflammation. The most remarkable and consistently reproducible quality of IL-10 is its ability to downregulate macrophage functions. This includes inhibiting the production of pro-inflammatory cytokines such TNF-alpha, Interleukin-1, Interleukin-6 and antigen presentation by these professional antigen presenting cells. Additionally, Interleukin-10 also has effects on various other cell types of hematopoietic origin such as B-cells, neutrophils, and most importantly T-cells. Interleukin-10 has shown efficacy in several models of autoimmune disease. The present article deals with the effect of Interleukin-10 in animal models of inflammatory bowel disease and the results of phase I clinical trials in normal human volunteers and chronic active Crohn's disease patients.

European trial of cyclosporine in chronic active Crohn's disease: A 12-month study: E.F. Stange, R. Modigliani, A.S. Pena, et al. Gastroenterology 109:774–782 (September), 1995

European trial of cyclosporine in chronic active Crohn's disease: A 12-month study: E.F. Stange, R. Modigliani, A.S. Pena, et al. Gastroenterology 109:774–782 (September), 1995

European trial of cyclosporine in chronic active Crohn's disease: A 12-month study

Background & Aims : The role of cyclosporine in Crohn's disease is controversial. This study aimed to delineate the long-term effect of cyclosporine in chronic active Crohn's disease. Methods : One hundred eighty-two patients from 33 European centers were included. The patient cohort was stratified at entry into a stratum with low Crohn's Disease Activity Index (CDAI) (<200) and high CDAI (>200). The low-activity group continued to receive the pretrial steroid dose for 2 months, and the high-activity group received 1 mg · kg −1 · day −1 prednisone initially. During months 3 and 4, the dose of steroids was reduced stepwise to 5 mg/day in all patients. Placebo and cyclosporine (5 mg · kg −1 · day −1) were administered throughout the 12-month study period. The main parameter of efficacy was the CDAI, and the main end point was the number of patients in remission at month 12. Results : During cyclosporine therapy, 35% (95% confidence interval [95% CI], 25%–46%) of the patients achieved a full remission (CDAI, <150) after 4 months compared with 27% (95% CI, 18%–38%) in the placebo group ( P > 0.05). At month 12, only 20% (95% CI, 12%–31%) vs. 20% (95% CI, 12%–31%) of the patients had maintained a continuous remission. No major differences between treatment groups were found within each of the two strata. Conclusions : The long-term treatment of chronic active Crohn's disease with cyclosporine plus low-dose steroids does not offer an advantage compared with low-dose steroids alone.

Methotrexate improved symptoms and reduced the need for prednisone in chronic active Crohn disease

Source Citation Feagan BG, Rochon J, Fedorak RN, et al. Methotrexate for the treatment of Crohn's disease. N Engl J Med. 1995 Feb 2;332:292-7.

Oral cyclosporin for chronic active Crohnʼs disease

Objective To determine the role of oral cyclosporin in the management of patients with chronic active Crohn's disease. Design Double-blind, placebo-controlled study of oral cyclosporin (5 mg/kg) versus placebo in combination with prednisolone over an initial period of 3 months. Patients The trial included 147 patients with chronic active Crohn's disease. Criteria for entry were as follows: patients with active disease requiring ≥10 mg prednisolone daily and/or azathioprine to control symptoms, and patients relapsing within 4 weeks of finishing one of these treatments. No case record form was completed for one patient. The data were analysed on an intention-to-treat basis for 146 patients. Outcome measures Clinical response was defined as the resolution of symptoms or a significant improvement on withdrawal or reduction of prednisolone. Disease activity was also assessed by the Harvey-Bradshaw Activity Index and laboratory indicators of activity (erythrocyte sedimentation rate, C-reactive protein). Results No significant differences were observed between the two groups with respect to clinical outcome, corticosteroid dosage required, or changes in the indices of activity over the 3-month trial period. Adverse reactions in the cyclosporin-treated patients were not uncommon, but none were serious or prolonged. Conclusion This trial does not support the value of oral cyclosporin (5 mg/kg) for the management of chronic active Crohn's disease.